EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age

Jean-François Roussy, Patrick Dennis, Anil K Gupta, Garry Wallace, Alexander Abitbol iD, Naresh Aggarwal, Joseph G Surber, Theodore Lee, Brian A Smith iD, Catherine Gérard, Hiwot Amare Hailemariam, Marie-Pierre David und 3 weitere

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciag208 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Jean-François Roussy und 14 weiteren Autor:innen. Beteiligte Einrichtung: DIEX Research, Québec, Québec, Canada. Hauptthemen laut MEDLINE: Herpes Zoster Vaccine, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Virus Infections, Adjuvants, Immunologic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Co-administration of AS01E-adjuvanted respiratory syncytial virus vaccine (adjuvanted RSVPreF3) and AS01B-adjuvanted recombinant herpes zoster subunit vaccine (RZV), although not contraindicated, has not been previously studied in clinical trials.

Methods

This phase III, open-label, randomized (1:1) trial evaluated the immunogenicity, safety, and reactogenicity of adjuvanted RSVPreF3 when co-administered with RZV in ≥50-year-olds. The 2 vaccines were either co-administered at visit 1 (day [D] 1; Co-Ad), or were given sequentially, 1 month apart (RZV dose 1 at D1, adjuvanted RSVPreF3 at D31; Control). All participants received RZV dose-2 at D61. Non-inferiority of humoral immune responses was demonstrated if 95% confidence interval (CI) upper limits for geometric mean RSV-A/B neutralizing titers (GMT) and varicella-zoster virus anti-glycoprotein E (anti-gE) antibody concentration (GMC) ratios (Control/Co-Ad) were ≤1.5. Safety and reactogenicity were secondary endpoints.

Results

Overall, 530 participants (Co-Ad = 265; Control = 265) were vaccinated. Neutralizing GMT ratios for RSV-A (1.1 [95% CI = 1.0–1.4]) and RSV-B (1.0 [0.8–1.2]), and anti-gE antibody GMC ratio (1.2 [1.1–1.4]) met non-inferiority criteria. Within 7 days post-vaccination, 71.7% (Co-Ad: post-RZV dose 1 and adjuvanted RSVPreF3; grade [Gr] 3 = 3.9%), 58.5% (Control: post-RZV dose 1; Gr3 = 1.9%), and 47.8% (Control: post-adjuvanted RSVPreF3; Gr3 = 1.2%) of participants reported solicited administration-site adverse events (AEs). Post-visit 1, 73.6% (Gr3 = 9.3%) of Co-Ad and 60.4% (Gr3 = 6.2%) of control participants reported solicited systemic AEs. Within 30 days post-any vaccination, 23.4% (Gr3 = 0.8%) of Co-Ad and 30.2% (Gr3 = 1.1%) of control participants reported unsolicited AEs. No fatal or related serious AEs were reported.

Conclusions

Immunogenicity, reactogenicity, and safety data support the co-administration of adjuvanted RSVPreF3 and RZV. Clinical Trials Registration NCT05966090.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpes Zoster VaccineRespiratory Syncytial Virus VaccinesRespiratory Syncytial Virus InfectionsAdjuvants, ImmunologicViral Fusion ProteinsImmunogenicity, VaccineRespiratory Syncytial Virus, HumanHumansFemaleAntibodies, ViralMaleMiddle AgedVaccines, SubunitAgedProtein Subunit VaccinesHerpes ZosterAdjuvants, VaccineVaccines, SyntheticAntibodies, NeutralizingAged, 80 and over

Stichwörter der Autor:innen

adjuvanted vaccinesco-administrationherpes zosterrespiratory syncytial virussafety

Substanzen

Herpes Zoster VaccineRespiratory Syncytial Virus VaccinesAntibodies, ViralAdjuvants, ImmunologicVaccines, SubunitViral Fusion ProteinsF protein, human respiratory syncytial virusProtein Subunit VaccinesAdjuvants, VaccineVaccines, Synthetic

Autor:innen und Institutionen

  • DIEX Research, Québec, Québec, Canada.
  • DELRIGHT Research, New Orleans, Louisiana, USA.
  • Albion Finch Medical Center, Toronto, Ontario, Canada.
  • Dawson Clinical Research, Guelph, Ontario, Canada.
  • LMC Healthcare/Centricity Research, Toronto, Ontario, Canada.
  • Aggarwal and Associates, Brampton, Ontario, Canada.

ORCID-Profile: Alexander Abitbol, Brian A Smith, Marie Van der Wielen

Förderung

  • GSK

Zitieren

APA

Roussy, J. F., Dennis, P., Gupta, A. K., Wallace, G., Abitbol, A., Aggarwal, N., Surber, J. G., Lee, T., Smith, B. A., Gérard, C., Hailemariam, H. A., David, M. P., Jastorff, A. M., Van der Wielen, M., & RSV-020 Study Group (2026). Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag208

Vancouver

Roussy JF, Dennis P, Gupta AK, Wallace G, Abitbol A, Aggarwal N, et al. Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag208

BibTeX
@article{Roussy2026,
  author = {Roussy, Jean-François and Dennis, Patrick and Gupta, Anil K and Wallace, Garry and Abitbol, Alexander and Aggarwal, Naresh and Surber, Joseph G and Lee, Theodore and Smith, Brian A and Gérard, Catherine and Hailemariam, Hiwot Amare and David, Marie-Pierre and Jastorff, Archana M and Van der Wielen, Marie and RSV-020 Study Group, RSV-020 Study Group},
  title = {Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults ≥ 50 Years of Age},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag208}
}
Kostenlos starten →